FDA Pushes New Approach To Alzheimer's Drug Development

Law360, New York (February 7, 2013, 7:22 PM EST) -- The U.S. Food and Drug Administration on Thursday proposed guidance for drugmakers in developing new treatments for patients in the early stages of Alzheimer's disease, part of a federal push to develop effective treatments for the degenerative and irreversible brain disease.

Alzheimer's is the most common cause of dementia among older people, according to the FDA, and the guidance addresses possible adaptations of the current approach to drug development for the treatment of the dementia stage of the disease that may be more appropriate for clinical...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.